$2.5 Billion Deal: Bristol-Meyers agrees to buy Inhibitex


Bristol-Myers Squibb Co. (NYSE: BMY) announced during morning trading in the stock market today that it will buy Alpharetta, Ga. based Inhibitex, Inc. (NASDAQ: INHX) for nearly $2.5 billion. Pending approval of the boards of directors of both companies, INHX is up over 140% today and over 500% since our first alert on INHX on November 4th.

The JP Morgan Healthcare Conference is well underway in S.F., California and companies in this sector will be breaking news like this as the week continues.  One such hopeful company is Generex Biotechnoloy (OTCBB: GNBT) which has completed Phase II trials of their breast cancer vaccine.  Hopes are that as we have alerted on GNBT that its chart will soon look similar to the following INHX chart below since the November 4th alert.

Inhibitex (NASDAQ: INHX) is a clinical-stage biopharmaceutical company developing products that can treat or prevent serious infections, whose primary focus is on the development of nucleotide/nucleoside analogs for the treatment of hepatitis C virus (HCV).

Inhibitex’s lead product is INX-189 is in Phase II development and has exhibited potent antiviral activity. Nucleotides/nucleosides are emerging as an important class of antivirals that may play a critical role as the backbone of future direct-acting antiviral-only combination approaches to HCV treatment.

Inhibitex ended the year with a $22.7 million loss in 2010 due to higher research and development expenses associated with a Phase 2 clinical trial of FV-100, the start of a Phase 1 clinical program for INX-189, an increase in other non-direct research and development costs, higher general and administrative expense and lower net interest income.

About AimHighProfits.com

AimHighProfits.com strives to provide you with the hottest stock alerts in the market in Real-Time. We focus on stocks that trade for $5 per share or less, some as little as a few pennies with upside potential. Our goal is committed to producing and publishing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions and to inform you of the best stocks in the market before they move. Our focus is primarily on OTC stocks in the stock market today which have traditionally been ignored by Wall Street.

We have particular expertise with internet stocks, gold stocks, renewable energy stocks, biotech stocks, oil stocks and green energy stocks. There are many hot penny stock opportunities present in the OTC market every day and we seek to exploit these hot stock gains for our members before the average daytrader is made aware of them.

Aim High Profits Disclaimer

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. AimHighProfits.com is a wholly-owned subsidiary of Kelevra Media Innovation.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Last updated by at .

  Recent Penny Stock News